Economics of dementia and pharmacoeconomics of dementia therapy.
BACKGROUND
The economic impact of dementia is not well appreciated, even though Alzheimer's disease and related dementias were the third most expensive health condition in the United States in 2000. In 1997, the cost of managing patients with Alzheimer's disease and other dementias was estimated at US dollar 100 billion. Direct medical costs are compounded by indirect costs of care, including unpaid care and loss of earnings.


OBJECTIVE
The aim of this review was to examine studies of the economic impact of approved treatments for dementia therapy.


METHODS
Searches of the MEDLINE database were conducted to identify prospective, randomized trials and retrospective or modeling studies of the economic impact of dementia medications, as well as analyses of managed care data (years 1996-2004; English language; search terms: dementia or Alzheimer's cross-referenced with economic or costs).


RESULTS
Only 3 studies directly examined the economic effects of dementia therapy. Two of these demonstrated economic benefits of treatment, whereas the third study concluded that there were no benefits; however, the conclusions of the latter study may have been weakened by such factors as the high rate of attrition and biased selection of study participants. Modeling studies and analyses of managed care data also indicate economic benefits from approved treatments.


CONCLUSIONS
Therapies that are efficacious early in the disease can postpone the progression of dementia to more severe stages and may offer economic benefit to patients' families, caregivers, and society.
Fillit
Howard
H
Institute for the Study of Aging, Inc., New York, New York 10019, USA. Hfillit@aging-institute.org
Hill
Jerrold
J
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy / Q000191:economics; D002800:Cholinesterase Inhibitors / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D003704:Dementia / Q000188:drug therapy* / Q000191:economics*; D017850:Economics, Pharmaceutical; D006801:Humans; D007326:Institutionalization; D016239:MEDLINE; D018803:Models, Economic; D018697:Nootropic Agents / Q000191:economics* / Q000627:therapeutic use*; D011446:Prospective Studies; D012189:Retrospective Studies
D002800:Cholinesterase Inhibitors; D018697:Nootropic Agents